Given these limitations of case–control analyses, insights from tumour sequencing, including identifying a “second hit” and characteristic genome alterations, may offer the best avenue for validating or refuting a role for RAD51C MS variants in BC predisposition. This evidence concerns the gene RAD51C and breast cancer.